Key facts
- It has raised $500K; the latest was Early Stage VC in Sep 2025.
- Notable investors include BioInnovation Institute, Science Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for GlioRay
- ·The full record, as it builds
Funding rounds
No funding rounds for GlioRay are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GlioRay
Developer of nanocarrier-based radioligand therapy technology intended to transform the way glioblastoma is treated. The company harnesses the power of Auger radioligand therapy combined with advanced nanocarriers to target cancer cells with unprecedented precision, helping patients minimize damage to surrounding healthy tissue and maximize therapeutic outcomes.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2024
- Employees
- 4
- Website
- glioray.com/
- Ownership
- Privately Held (backing)
GlioRay doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GlioRay shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GlioRay in its N-PORT filings yet. We sweep new filings monthly.